Group 1 - The stock price of Jianfa Zhixin (301584) closed at 31.57 yuan on December 25, 2025, down 0.79%, with a turnover rate of 9.19%, a trading volume of 46,300 shares, and a transaction amount of 146 million yuan [1] - The company has experienced growth in its main products, including high-value medical consumables, despite the implementation of centralized procurement policies since 2020 [1] - The company is focusing on diversifying its product offerings and expanding into innovative medical device distribution, while also adapting to the DRGS policy for efficient management of hospital consumables [1] Group 2 - On December 25, the net outflow of main funds was 18.3961 million yuan, while retail investors saw a net inflow of 18.8275 million yuan [2][3] - Senior management member Cheng Fang resigned from her position as Vice General Manager for personal reasons but will continue to work at the company [2][3] - Cheng Fang does not directly hold company shares but has indirect holdings through an employee stock ownership plan and stock options [2]

Core Viewpoint - The company emphasizes that the centralized procurement policy for medical devices is beneficial for the long-term healthy development of the medical device industry in China, despite concerns about its impact on profitability and the need for diversification into new business areas [1]. Group 1: Industry Insights - The centralized procurement policy, which aims to save costs for the medical insurance fund and residents, has been in place since 2020, leading to a growth phase in the medical device industry [1]. - The company’s main products, high-value medical consumables, have undergone multiple rounds of centralized procurement, covering areas such as vascular intervention, surgical medical consumables, and IVD diagnostic products [1]. Group 2: Company Strategy - The company has strategically diversified its product offerings to mitigate revenue fluctuations from single products and has actively developed distribution for innovative medical devices [1]. - In response to the DRGS policy and the demand for lean management of hospital consumables, the company has also expanded into SPD management services [1]. - The management is focused on high-quality development and is strategically evaluating new business forms, digital technologies, and service areas for potential inclusion in the company's growth strategy [1].

Core Viewpoint - The company, Jianfa Zhixin (301584), primarily engages in the distribution and direct sales of medical devices, including high-value medical consumables and IVD diagnostic products, and does not currently involve in the sales of innovative drug projects [1] Group 1 - The main business activities of the company include the distribution and direct sales of medical devices [1] - The company focuses on high-value consumables and IVD diagnostic products [1] - There is no involvement in the sales of innovative drug projects at this time [1]

Group 1 - The company, Jianfa Zhixin (301584.SZ), confirmed that its main business involves the distribution and direct sales of medical devices, such as high-value medical consumables and IVD diagnostic products [2] - The company does not engage in the sales of innovative drug projects [2]